A human study to evaluate safety and effectiveness of AB2024W on body fat level and related metabolim in obese adults.

Bundang CHA General Hospital0 个研究点目标入组 100 人开始时间: 待定最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1) Subject who voluntarily agree to participate and signs informed consent form
•2) Aged more than 19 years and less less than 75 years, women and men
•3) Those who have a body mass index (BMI) of 25kg/m*2 or more and less than 30kg/m*2
•4) Those who have waist circumference of more than 90cm for men and 85cm for women

•1) Subjects with the following diseases: Chronic inflammatory diseases, diabetes, liver disease, kidney disease, cardiovascular disease, hypertension, etc.
•2) Continued use of health functional food or medicines or oriental medicines
•3) Subjects with low body fat percentage
•4) Those who have participated in commercial obesity programs or received calorific dietary treatment within three months of their first visit.
•5) Participation in another clinical study within 1 month before the first visit
•6) Pregnant or lactating women, or women planning to be pregnant
•7) Hypersensitivity to the ingredients contained in the test·control food or experience of severe food allergic reactions
•8) Any condition that the investigator considers inappropriate to participate in this study

发起方

Bundang CHA General Hospital